Preclinical targeting of aggressive T-cell malignancies using anti-CD5 chimeric antigen receptor. - Wikidata - wikimedia - TriplyDB

Preclinical targeting of aggressive T-cell malignancies using anti-CD5 chimeric antigen receptor.

Preclinical targeting of aggressive T-cell malignancies using anti-CD5 chimeric antigen receptor.

http://www.wikidata.org/entity/Q38722015

about

Chimeric Antigen Receptor-Engineered NK-92 Cells: An Off-the-Shelf Cellular Therapeutic for Targeted Elimination of Cancer Cells and Induction of Protective Antitumor Immunity Chimeric antigen receptor-engineered natural killer and natural killer T cells for cancer immunotherapy.Chimeric antigen receptor (CAR)-modified natural killer cell-based immunotherapy and immunological synapse formation in cancer and HIV.Engineering Natural Killer Cells for Cancer Immunotherapy.Natural Killer Cells: Angels and Devils for Immunotherapy.Synergistic Effects of Cabozantinib and EGFR-Specific CAR-NK-92 Cells in Renal Cell Carcinoma.A compound chimeric antigen receptor strategy for targeting multiple myeloma.Targeting T-cell malignancies using anti-CD4 CAR NK-92 cells.Development of GPC3-Specific Chimeric Antigen Receptor-Engineered Natural Killer Cells for the Treatment of Hepatocellular Carcinoma.Development of chimeric antigen receptors targeting T-cell malignancies using two structurally different anti-CD5 antigen binding domains in NK and CRISPR-edited T cell lines.Compound CAR T-cells as a double-pronged approach for treating acute myeloid leukemia.Chimeric Antigen Receptor Expressing Natural Killer Cells for the Immunotherapy of Cancer.Natural Killer Cells in Liver Disease and Hepatocellular Carcinoma and the NK Cell-Based Immunotherapy Unleashing the Therapeutic Potential of CAR-T Cell Therapy Using Gene-Editing Technologies Natural Killer Cells: Development, Maturation, and Clinical Utilization

P2860

Q33700795-A3DC00D9-3B04-4764-852E-A6BB7ABEABCF Q38666579-7715709A-4451-4EEB-B01F-BF2097F0E449 Q38685785-2EC4C38F-491D-4AD5-A2F2-CC42D5E9251A Q39408704-9CBFBF4B-4AA1-4732-88C3-3FBCF5F23681 Q41661175-A552632B-7C26-4049-BEED-CD5FF0DE1F4E Q48504970-D9FEA665-C3B9-4E6B-BA77-D267CC890186 Q48649390-517D0535-735C-4BEE-BF6A-1D0F9A1953FA Q49290997-CB197F30-319B-4EE7-A139-160C61E23FC4 Q50022186-1D3E183C-20E9-40D0-B0AD-00D3E126EB39 Q52430204-DD560728-42AB-450F-ADFA-B9DB5F8EFC9A Q52728078-E7252655-0CC9-4B51-BFFC-015707CD6B91 Q53705286-7E1CE074-6124-44D8-9BBE-C387ED8DDB53 Q58764532-DBF248CC-C745-47A3-8B0D-B9D6DB8DD371 Q58780007-CA82BDF0-B6C5-4709-A9B9-1F7891582D61 Q58785734-2E833F62-F0E5-4EF4-81C3-E0C6B6C361E1

P2860

Preclinical targeting of aggressive T-cell malignancies using anti-CD5 chimeric antigen receptor.

http://www.wikidata.org/entity/Q38722015

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Preclinical targeting of aggre ...... CD5 chimeric antigen receptor.

@en

type

label

Preclinical targeting of aggre ...... CD5 chimeric antigen receptor.

@en

prefLabel

Preclinical targeting of aggre ...... CD5 chimeric antigen receptor.

@en

P1433

Q38722015-19DB243C-F440-47F3-ACF8-660D9B489E6B

P1476

Q38722015-286652C4-7924-4AE7-9AAC-95A9205CD7F9

P2093

Q38722015-1E36F3D6-04FA-4C8A-92E1-BBC570DFD8B6

Q38722015-29E0F085-1A27-4C7F-B256-AE7FEDA16041

Q38722015-359FE991-9454-4696-BB51-3F263A790774

Q38722015-37844B47-0A24-4485-AABA-DA5F25441AB4

Q38722015-4147CAD5-1850-409E-8BD0-8CCC41787594

Q38722015-433E6FDA-9C17-435F-B74F-077D9AADFCBD

Q38722015-46604EED-D7EC-41B3-A9DE-E2AABEF3C4D2

Q38722015-5D95ECDA-67A8-495A-983E-372541F8AAE4

Q38722015-AF48A04F-06DC-486B-96B1-5935A50CB246

Q38722015-C667A122-CE8C-4C6F-B9FD-CC8E190F302E

P2860

Q38722015-102D32CB-E020-4C7B-9AB4-D7396F1CA431

Q38722015-14E23201-1A05-4182-B4C6-93AC534DA242

Q38722015-1C09E7EB-377E-4EF4-9815-947238948591

Q38722015-1C756307-357B-4893-A448-795F0FC3DDA9

Q38722015-1D67FA76-D901-43E1-83C6-555BE27B9279

Q38722015-2EE25231-14E5-424E-97B8-9A01F452CB95

Q38722015-3AE7A0EE-FD7F-438A-8BE9-40C3E1087942

Q38722015-407AC8BE-673C-40DB-854C-95634EA75416

Q38722015-42D3D74B-F812-4B83-94C6-DDAD2628364A

Q38722015-54105501-B925-48A6-B3E1-5E6A1BD86583

P2888

Q38722015-68D9CDD1-916A-4B69-9C5B-AC195CF998C1

P304

Q38722015-7CD65324-A60C-4CF8-AD33-25837847E1DE

P31

Q38722015-21C65A36-70A9-422F-B734-5A8564FB13A5

P356

Q38722015-1652BC98-9AE2-467B-8707-9CC1D8800A29

P433

Q38722015-25CBC2A7-C4ED-47EB-A390-C0B1A2EB61A4

P478

Q38722015-7716CAF8-9993-42E4-9718-4F222AA26BB9

P50

Q38722015-02BA1DDE-B377-4A0E-A2A6-349144D694F3

Q38722015-0BB4913F-F7E7-4392-827F-6C837243D2D4

P577

Q38722015-2116DD2E-C0CB-41C4-B710-79E8478A4B6D

P6179

Q38722015-4F45259C-86BB-4009-A202-85A4B5C5817B

P698

Q38722015-B6A34B20-C0B9-428F-925A-51D365D0B08C

P932

Q38722015-CD308F1A-09A6-4C78-B63A-D3148F61FA0C

P356

P1433

P1476

Preclinical targeting of aggre ...... -CD5 chimeric antigen receptor

@en

P2093

E L Leung

http://www.w3.org/2001/XMLSchema#string

F Lan

http://www.w3.org/2001/XMLSchema#string

H Liu

http://www.w3.org/2001/XMLSchema#string

H Salman

http://www.w3.org/2001/XMLSchema#string

K G Pinz

http://www.w3.org/2001/XMLSchema#string

K H Chen

http://www.w3.org/2001/XMLSchema#string

K-W Lin

http://www.w3.org/2001/XMLSchema#string

L Senzel

http://www.w3.org/2001/XMLSchema#string

M Golightly

http://www.w3.org/2001/XMLSchema#string

M Wada

http://www.w3.org/2001/XMLSchema#string

P2860

Natural Killer Cells for Immunotherapy - Advantages of the NK-92 Cell Line over Blood NK Cells

Selective inhibition of tumor growth by clonal NK cells expressing an ErbB2/HER2-specific chimeric antigen receptor

Advantages and applications of CAR-expressing natural killer cells

Cellular Immunotherapy of Malignancies Using the Clonal Natural Killer Cell Line NK-92

CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia

Development of an inducible caspase-9 safety switch for pluripotent stem cell-based therapies

A T-cell-directed chimeric antigen receptor for the selective treatment of T-cell malignancies

Retargeting NK-92 cells by means of CD19- and CD20-specific chimeric antigen receptors compares favorably with antibody-dependent cellular cytotoxicity.

CS1-specific chimeric antigen receptor (CAR)-engineered natural killer cells enhance in vitro and in vivo antitumor activity against human multiple myeloma

The role of natural killer cells in immunity against multiple myeloma.

P2888

P304

2151-2160

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/LEU.2017.8

http://www.w3.org/2001/XMLSchema#string

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

31

http://www.w3.org/2001/XMLSchema#string

P50

Alexander Jares

P577

2017-01-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1052261154

http://www.w3.org/2001/XMLSchema#string

P698

28074066

http://www.w3.org/2001/XMLSchema#string

P932

5629371

http://www.w3.org/2001/XMLSchema#string